Israeli investigators intend to evaluate the potential anti-tumoral effects of the canabinoid cannabidiol (CBD) in select cancer patients.
Researchers at the Hassadah Medical Center in Jerusalem will conduct a Phase II clinical trial to assess the impact of CBD as single treatment in cancer patients who have failed to respond to conventional therapies. Participants in the trial will receive CBD therapy for a period of eight weeks.
Data documenting the potent anti-cancer activity of various cannabinoids – including THC, CBD, and CBG – both in culture and in animals dates back to the mid-1970s. To date, however, virtually no clinical trials exist reproducing these results in human subjects.
In August, pharmaceutical provider Insys Therapeutics announced that it had received orphan drug status for its proprietary formulation of CBD for the treatment of glioblastoma, a hard-to-treat, aggressive form of brain cancer.
Organic CBD remains classified under federal law as a schedule I controlled substance.
Further details of the forthcoming Israeli trial are available online from the clinicaltrials.gov website here. Patient recruitment has yet to begin for this study.
View full post on NORML Blog, Marijuana Law Reform